Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
15-valent HPV vaccine (Shanghai Bovax)
- Development stage
- Unknown
- Lead developer
- Shanghai Bovax Biotechnology
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The 15-valent HPV vaccine is a recombinant biologic vaccine developed by Shanghai Bovax Biotechnology Co., Ltd. using Virus-Like Particles (VLPs) technology expressed in the *Hansenula polymorpha* yeast system. This vaccine is designed to provide broad protection against 15 types of Human Papillomavirus (HPV), including all 12 high-risk types identified by the International Agency for Research on Cancer (IARC). By expanding coverage beyond the currently marketed 9-valent vaccines, it is estimated to prevent approximately 99% of cervical cancers. The vaccine is indicated for the prevention of HPV infection, HPV-related carcinomas (such as cervical, vaginal, and vulvar cancers), intraepithelial neoplasia, and genital warts. It is administered via intramuscular injection in a three-dose schedule (0, 2, and 6 months) and is currently in Phase 2 clinical development in China for individuals aged 9 to 45 years.
- Other names
- 15-valent Recombinant Human Papillomavirus Vaccine (Hansenula polymorpha)15-valent HPV vaccine15-valent recombinant human papillomavirus vaccine
Beyond the preview
Go deeper on 15-valent HPV vaccine (Shanghai Bovax).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 15-valent HPV vaccine (Shanghai Bovax).